An orally active formulation of angiotensin-(1-7) produces an antithrombotic effect

Clinics

Volumn 66, Issue 5, 2011, Pages 837-841

  Fraga Silva, Rodrigo Araujo ^a   Costa Fraga, Fabiana P ^a   de Sousa, Frederico B ^b   Alenina, Natalia ^c   Bader, Michael ^c   Sinisterra, Ruben D ^b   Santos, Robson A S ^a  

^a Biological Science Institute   (Brazil)

^b FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^c MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

Author keywords

Angiotensin (1 7); Antithrombotic; Cyclodextrin; Receptor Mas; Renin angiotensin system

Indexed keywords

ANGIOTENSIN I; ANGIOTENSIN I (1 7); ANGIOTENSIN I (1-7); FIBRINOLYTIC AGENT; PEPTIDE FRAGMENT;

ANIMAL; ARTICLE; C57BL MOUSE; DISEASE MODEL; DOSE RESPONSE; MALE; MOUSE; MOUSE MUTANT; RAT; SPONTANEOUSLY HYPERTENSIVE RAT; VEIN THROMBOSIS;

ANGIOTENSIN I; ANIMALS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FIBRINOLYTIC AGENTS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PEPTIDE FRAGMENTS; RATS; RATS, INBRED SHR; VENOUS THROMBOSIS;

EID: 79960879235     PISSN: 18075932     EISSN: None     Source Type: Journal    
DOI: 10.1590/S1807-59322011000500021     Document Type: Article

References (26)

1. Willoughby S, Holmes A, Loscalzo J, Platelets and cardiovascular disease. Eur J Cardiovasc Nurs. 2002;1:273-88 doi: 10.1016/S1474- 5151(02)00038-5.
2. Lip GY. Hypertension, platelets, and the endothelium: the thrombotic paradox of hypertension (or Birmingham paradox) revisited. Hypertension. 2003;41:199-200 doi: 10.1161/01.HYP.0000049761.98155. 7B.
3. Kucharewicz I, Pawlak R, Matys T, Chabielska E, Buczko W. Angiotensin-(1-7): an active member of the renin-angiotensin system. J Physiol Pharmacol. 2002;53:533-40.
4. HOPE Investigators. Effects of ramipril on cardiovascular and micro- vascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet. 2000; 355:253-9 doi: 10.1016/ S0140-6736(99)12323-7.
5. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet. 2002; 359:995-1003 doi: 10.1016/S0140- 6736(02)08089-3.
6. Ferrario CM, Chappell MC, Tallant EA, Brosnihan KB, Diz DI. Counterregulatory actions of angiotensin-(1-7). Hypertension. 1997;30:535-41.
7. Santos RA, Campagnole-Santos MJ, Andrade SP. Angiotensin-(1-7): an update. Regul Pept. 2000;91:45-62 doi: 10.1016/S0167-0115(00)00138-5.
8. Santos RA, Ferreira AJ, Pinheiro SV, Sampaio WO, Touyz R, Campagnole-Santos MJ. Angiotensin-(1-7) and its receptor as a potential targets for new cardiovascular drugs. Expert Opin Investig Drugs. 2005;14:1019-31 doi: 10.1517/13543784.14.8.1019.
9. Trask AJ, Ferrario CM, Angiotensin-(1-7): pharmacology and new perspectives in cardiovascular treatments. Cardiovasc Drug Rev. 2007;25:162-74 doi: 10.1111/j.1527-3466.2007.00012.x.
10. Kucharewicz I, Pawlak R, Matys T, Pawlak D, Buczko W. Antithrombotic effect of captopril and losartan is mediated by angiotensin-(1-7). Hypertension. 2002;40:774-9 doi: 10.1161/01.HYP.0000035396.27909.40.
11. Iyer SN, Ferrario CM, Chappell MC. Angiotensin-(1-7) contributes to the antihypertensive effects of blockade of the renin-angiotensin system. Hypertension. 1998;31:356-61.
12. Fraga-Silva RA, Pinheiro SV, Gonçalves AC, Alenina N, Bader M, Santos RA. The antithrombotic effect of angiotensin-(1-7) involves mas- mediated NO release from platelets. Mol Med. 2008;14:28-35.
13. Santos RA, Simoes e Silva AC, Maric C, Silva DM, Machado RP, de Buhr I, et al. Angiotensin-(1-7) is an endogenous ligand for the G protein- coupled receptor Mas. Proc Natl Acad Sci U S A. 2003;100:8258-63 doi: 10.1073/pnas.1432869100.
14. Uekama K. Design and evaluation of cyclodextrin-based drug formula- tion. Chem Pharm Bull (Tokyo). 2004;52:900-15 doi: 10.1248/cpb.52.900.
15. Lula I, Denadai AL, Resende JM, de Sousa FB, de Lima GF, Pilo-Veloso D, et al. Study of angiotensin-(1-7) vasoactive peptide and its beta- cyclodextrin inclusion complexes: Complete sequence-specific NMR assignments and structural studies. Peptides. 2007;28:2199-2210 doi: 10. 1016/j.peptides.2007.08.011.
16. Mendes AC, Ferreira AJ, Pinheiro SV, Santos RA. Chronic infusion of angiotensin-(1-7) reduces heart angiotensin II levels in rats. Regul Pept. 2005;125:29-34 doi: 10.1016/j.regpep.2004.07.023.
17. Botelho LM, Block CH, Khosla MC, Santos RA. Plasma angiotensin(1-7) immunoreactivity is increased by salt load, water deprivation, and hemorrhage. Peptides. 1994;15:723-9 doi: 10.1016/0196-9781(94)90103-1.
18. Brosnihan KB, Li P, Ferrario CM. Angiotensin-(1-7) dilates canine coronary arteries through kinins and nitric oxide. Hypertension. 1996;27:523-8.
19. Neves LAA, Almeida AP, Khosla MC, Campagnole-Santos MJ, Santos RAS. Effect of angiotensin-(1-7) on reperfusion arrhythmias in isolated rat hearts. Brazilian Journal of Medical and Biological Research. 1997;30:801-9 doi: 10.1590/S0100-879X1997000600016.
20. Ferreira AJ, Santos RAS, Almeida AP. Angiotensin-(1-7): cardioprotective effect in myocardial ischemia/reperfusion. Hypertension. 2001;38:665-8.
21. Loot AE, Roks AJM, Henning RH, Tio RA, Suurmeijer AJH, Boomsma F, et al. Angiotensin-(1-7) attenuates the development of heart failure after myocardial infarction in rats. Circulation. 2002;105:1548-50 doi: 10.1161/ 01.CIR.0000013847.07035.B9.
22. Katovich MJ, Grobe JL, Raizada MK. Angiotensin-(1-7) as an antihy- pertensive, antifibrotic target. Curr Hypertens Rep. 2008;10:227-32 doi: 10.1007/s11906-008-0043-9.
23. Faria-Silva R, Duarte FV, Santos RA. Short-term angiotensin(1-7) receptor MAS stimulation improves endothelial function in normoten- sive rats. Hypertension. 2005;46:948-52 doi: 10.1161/01.HYP.0000174594. 17052.33.
24. Santos RA, Ferreira AJ, Simo ̃es E Silva AC. Recent advances in the angiotensin-converting enzyme 2-angiotensin(1-7)-Mas axis. Exp Physiol. 2008;93:519-27 doi: 10.1113/expphysiol.2008.042002.
25. Loscalzo J. Nitric oxide insufficiency, platelet activation, and arterial thrombosis. Circ. Res. 2001;88:756-62 doi: 10.1161/hh0801.089861.
26. Willoughby S, Holmes A, Loscalzo J. Platelets and cardiovascular disease. Eur. J. Cardiovasc. Nurs. 2002;1:273-88 doi: 10.1016/S1474- 5151(02)00038-5.